Comments
Loading...

Prime Medicine

PRMENASDAQ
Logo brought to you by Benzinga Data
$2.90
0.000.00%
Pre-Market: Dec 20, 4:03 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$25.00
Lowest Price Target1
$10.00
Consensus Price Target1
$16.29

Prime Medicine (NASDAQ:PRME) Stock, Analyst Ratings, Price Targets, Forecasts

Prime Medicine Inc has a consensus price target of $16.29 based on the ratings of 15 analysts. The high is $25 issued by Jefferies on November 14, 2022. The low is $10 issued by JMP Securities on December 10, 2024. The 3 most-recent analyst ratings were released by JMP Securities, Guggenheim, and Chardan Capital on December 10, 2024, December 3, 2024, and November 13, 2024, respectively. With an average price target of $14.33 between JMP Securities, Guggenheim, and Chardan Capital, there's an implied 394.25% upside for Prime Medicine Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Aug
2
Oct
2
Nov
1
Dec
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

JMP Securities
Guggenheim
Chardan Capital
HC Wainwright & Co.
Citigroup

1calculated from analyst ratings

Analyst Ratings for Prime Medicine

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Prime Medicine (PRME) stock?

A

The latest price target for Prime Medicine (NASDAQ:PRME) was reported by JMP Securities on December 10, 2024. The analyst firm set a price target for $10.00 expecting PRME to rise to within 12 months (a possible 244.83% upside). 18 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Prime Medicine (PRME)?

A

The latest analyst rating for Prime Medicine (NASDAQ:PRME) was provided by JMP Securities, and Prime Medicine initiated their market outperform rating.

Q

When was the last upgrade for Prime Medicine (PRME)?

A

The last upgrade for Prime Medicine Inc happened on May 16, 2024 when Citigroup raised their price target to $10. Citigroup previously had a neutral for Prime Medicine Inc.

Q

When was the last downgrade for Prime Medicine (PRME)?

A

There is no last downgrade for Prime Medicine.

Q

When is the next analyst rating going to be posted or updated for Prime Medicine (PRME)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prime Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prime Medicine was filed on December 10, 2024 so you should expect the next rating to be made available sometime around December 10, 2025.

Q

Is the Analyst Rating Prime Medicine (PRME) correct?

A

While ratings are subjective and will change, the latest Prime Medicine (PRME) rating was a initiated with a price target of $0.00 to $10.00. The current price Prime Medicine (PRME) is trading at is $2.90, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch